Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.

Secondary bile acids (BA) such as deoxycholic acid (DCA) promote the development of several gastrointestinal malignancies, but how they mediate this effect is unclear. In this study, we offer evidence of a mechanism involving ectodomain shedding of the EGFR ligands amphiregulin (AREG) and TGF-α, which rely upon the cell surface protease TACE/ADAM-17. Specifically, we show that AREG participates in DCA-induced EGFR and STAT3 signaling, cell-cycle progression, and tumorigenicity in human colorectal cancer and pancreatic ductal adenocarcinoma (PDAC). TACE and AREG, but not TGF-α, were overexpressed in both colorectal cancer and PDAC tissues compared with normal tissues. Exposure of colorectal cancer and PDAC cells to DCA resulted in colocalization of Src and TACE to the cell membrane, resulting in AREG-dependent activation of EGFR, mitogen-activated protein kinase (MAPK), and STAT3 signaling. Src or TACE inhibition was sufficient to attenuate DCA-induced AREG, but not TGF-α shedding. We also examined a role for the BA transporter TGR5 in DCA-mediated EGFR and STAT3 signaling. RNA interference-mediated silencing of TGR5 or AREG inhibited DCA-induced EGFR, MAPK, and STAT3 signaling, blunted cyclin D1 expression and cell-cycle progression, and attenuated DCA-induced colorectal cancer or PDAC tumorigenicity. Together, our findings define an AREG-dependent signaling pathway that mediates the oncogenic effects of secondary BAs in gastrointestinal cancers, the targeting of which may enhance therapeutic responses in their treatment.

[1]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[2]  Masahira Hattori,et al.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.

[3]  J. Auwerx,et al.  The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.

[4]  C. Blobel,et al.  A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17 , 2011, Oncogene.

[5]  M. Washington,et al.  Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth , 2011, Clinical Cancer Research.

[6]  S. Shak,et al.  Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer , 2011, British Journal of Cancer.

[7]  M. Washington,et al.  Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis , 2010, Molecular Cancer Therapeutics.

[8]  L. Sancey,et al.  Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Jie Hong,et al.  Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma , 2009, Gut.

[10]  H. Bernstein,et al.  Bile acids as endogenous etiologic agents in gastrointestinal cancer. , 2009, World journal of gastroenterology.

[11]  O. Sansom,et al.  A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. , 2009, Carcinogenesis.

[12]  Armanda D. Tatsas,et al.  Epithelial-Mesenchymal Transition Markers in Pancreatic Ductal Adenocarcinoma , 2009, Pancreas.

[13]  H. Kung,et al.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530 , 2008, Oncogene.

[14]  P. Johnston,et al.  Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. , 2008, Cancer research.

[15]  H. Bernstein,et al.  Field defects in progression to gastrointestinal tract cancers. , 2008, Cancer letters.

[16]  B. LaFleur,et al.  TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer , 2008, Clinical Cancer Research.

[17]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[18]  M. Bissell,et al.  Targeting TACE-dependent EGFR ligand shedding in breast cancer. , 2007, The Journal of clinical investigation.

[19]  Nadarajah Vigneswaran,et al.  Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. , 2006, Toxicology letters.

[20]  David C. Lee,et al.  Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. , 2006, Cancer research.

[21]  G. Mills,et al.  Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Nagaraj,et al.  Hypoxia inhibits TRAIL-induced tumor cell apoptosis: Involvement of lysosomal cathepsins , 2006, Apoptosis.

[23]  Yusuke Nakamura,et al.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.

[24]  Ho-Yyoung Lee,et al.  Resistance to epidermal growth factor receptor-targeted therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  J. Morrow,et al.  Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. , 2005, Surgery.

[26]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[27]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[29]  D. Schuppan,et al.  Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. , 2004, Journal of hepatology.

[30]  G. Jenkins,et al.  The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. , 2003, Carcinogenesis.

[31]  R. Coffey,et al.  Transforming Growth Factor-Alpha (TGF-alpha) Levels in Human Proximal Gastrointestinal Epithelium (Effect of Mucosal Injury and Acid Inhibition) , 1997, Digestive Diseases and Sciences.

[32]  Stefan Hart,et al.  TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells , 2003, The EMBO journal.

[33]  David C. Lee,et al.  TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase , 2003, Annals of the New York Academy of Sciences.

[34]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[35]  Robert J Coffey,et al.  EGF receptor ligands. , 2003, Experimental cell research.

[36]  D. Wakelin,et al.  Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.

[37]  T. Yeatman,et al.  Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. , 2002, Cancer research.

[38]  G. Gores,et al.  Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. , 2002, Gastroenterology.

[39]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[40]  M. Mareel,et al.  The role of bile acids in carcinogenesis. , 2001, Mutation research.

[41]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[42]  E. Rozengurt,et al.  EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. , 2001, American journal of physiology. Cell physiology.

[43]  Jesse D. Martinez,et al.  Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. , 2001, Carcinogenesis.

[44]  G. Carpenter Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways , 1999, The Journal of cell biology.

[45]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[46]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[47]  A. Ullrich,et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.

[48]  G. Paumgartner,et al.  Increased serum deoxycholic acid levels in men with colorectal adenomas. , 1993, Gastroenterology.

[49]  N. Normanno,et al.  Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. , 1992, Cancer research.

[50]  R. Coffey,et al.  Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. , 1992, Cancer research.